TP53 and glioma: Given the limited efficacy of current standards of therapy in gliomas, multiple studies and clinical trials over the past decade have shifted to targeted therapy as an alternative with p53, retinoblastoma (RB), EGFR, FGFR and the proteasome being a few examples (5).